Structure Therapeutics Inc.

NasdaqGM:GPCR 株式レポート

時価総額：US$2.8b

Structure Therapeutics バランスシートの健全性

財務の健全性 基準チェック /66

Structure Therapeuticsの総株主資本は$1.4B 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$1.5Bと$61.0Mです。

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオn/a
現金US$1.46b
エクイティUS$1.45b
負債合計US$61.03m
総資産US$1.51b

財務の健全性に関する最新情報

分析記事 • Jun 24

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Mar 11

We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Nov 25

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Aug 11

We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Mar 10

Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Seeking Alpha • Apr 08

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

Summary Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario. Phase 3 Aleniglipron trial is the key catalyst, with a modeled 67.7% probability of success and potential $6B peak global sales. Read the full article on Seeking Alpha
分析記事 • Jun 24

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 20

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Summary Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge. With experienced management and multiple upcoming catalysts, Structure could see significant value growth or a potential Big Pharma acquisition. Read the full article on Seeking Alpha
分析記事 • Mar 11

We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Structure Therapeutics: Competitive Data Is Emerging

Summary Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron demonstrated superior weight loss, but GSBR-1290's late improvements indicate it might catch up with extended treatment. Financially, Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully realized yet. The weight loss market is projected to reach $200bn by 2029, offering significant prospects for GSBR-1290 despite competitive and developmental risks. Read the full article on Seeking Alpha
分析記事 • Nov 25

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 22

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Summary Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024. LTSE-2578 is being developed in phase 1 study targeting patients with idiopathic pulmonary fibrosis; the global idiopathic pulmonary fibrosis market is expected to reach $11.7 billion by 2031. Read the full article on Seeking Alpha
分析記事 • Aug 11

We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 14

Structure Therapeutics: Yet Another Potential GLP-1 Entrant

Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatment landscape. The company used the spike in the stock to raise additional capital this month. Can Structure compete against Eli Lilly, Novo Nordisk and a host of other potential entrants in an increasingly crowded GLP-1 space? We look at the GLP-1 competitive landscape as well as Structure's prospects in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jun 05

Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape

Summary Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo. Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting. The financial outlook is stable with over three years of cash runway. Hold recommendation for GPCR stock; GSBR-1290 has potential, but competition and adverse effects warrant caution. Read the full article on Seeking Alpha
分析記事 • Mar 10

Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jun 29

Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

財務状況分析

短期負債: GPCRの 短期資産 ( $1.5B ) が 短期負債 ( $57.0M ) を超えています。

長期負債: GPCRの短期資産 ( $1.5B ) が 長期負債 ( $4.0M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: GPCRは負債がありません。

負債の削減: GPCR過去 5 年間負債を抱えていません。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: GPCRは、現在の フリーキャッシュフロー に基づき、3 年以上にわたって十分な キャッシュランウェイ を有しています。

キャッシュランウェイの予測: GPCRフリーキャッシュフローが毎年41.1 % の歴史的率で減少し続ける場合、3 年以上にわたって十分なキャッシュランウェイを持っています。

健全な企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/22 12:45
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Structure Therapeutics Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22

アナリスト機関
Evan SeigermanBMO Capital Markets Equity Research
Edward NashCanaccord Genuity
Prakhar AgrawalCantor Fitzgerald & Co.